Ratio to to receive upfront, and potential milestones and tiered royalty payments BOSTON, November 18, 2024 /PRNewswire/ — Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, entered today into an exclusive worldwide license Read more

BOSTON, June 20, 2024 – Ratio Therapeutics Inc. (Ratio), an emerging pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointment of Former U.S. Senator William “Mo” Cowan to its Board of Directors. Senator Read more

BOSTON, May 6, 2024 – Ratio Therapeutics Inc. (Ratio), an emerging pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointment of Marc Becker as the company’s Chief Financial Officer and Chief Operating Officer. Read more

BOSTON, April 2, 2024 – Ratio Therapeutics Inc. (Ratio), an emerging pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointments of Bill Cupelo as the company’s Chief Business Officer and D. Scott Holbrook, Read more

BOSTON, MA and BOCA RATON, FL –  March 12th, 2024 – Ratio Therapeutics Inc. (Ratio), an emerging pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced an expanded manufacturing agreement with PharmaLogic, a world-class contract Read more

Boston-Based Radiopharmaceutical Company Brings Total Financing to More Than $90Million Since 2021 Launch BOSTON, January 17, 2024 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class radiopharmaceuticals for the treatment and monitoring of Read more